{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:58:22Z","timestamp":1793534302735,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110030","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:20:52Z","timestamp":1700828452000},"page":"110030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-889X","authenticated-orcid":false,"given":"Cole","family":"Friedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Iocolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-3399","authenticated-orcid":false,"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-433X","authenticated-orcid":false,"given":"Abigail","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-2964","authenticated-orcid":false,"given":"Lova L.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Cengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon-Keng Kevin","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-6811","authenticated-orcid":false,"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3047-3151","authenticated-orcid":false,"given":"Jeffrey","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-0040","authenticated-orcid":false,"given":"Steven J.","family":"Feigenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4946-2348","authenticated-orcid":false,"given":"Nikhil","family":"Yegya-Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110030_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0010","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.110030_b0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110030_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.110030_b0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","article-title":"Harnessing the immune system for the treatment of non-small-cell lung cancer","volume":"31","author":"Brahmer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0030","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","article-title":"Non-Small cell lung cancer: role of the immune system and potential for immunotherapy","volume":"10","author":"Carbone","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"154","author":"Friedes","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110030_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2022.01.007","article-title":"Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy","volume":"168","author":"Cho","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0045","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1186479","article-title":"Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer","volume":"13","author":"Pasquier","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0055","article-title":"Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC","volume":"3","author":"Jing","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2023.110030_b0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2022.12.030","article-title":"Proton and carbon ion radiation therapy decreased severe lymphopenia by reducing thoracic vertebra and aortic doses in non-small cell lung cancer versus intensity modulated radiation therapy","volume":"116","author":"Li","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110030_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2023.110030_b0070","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13277-015-3888-y","article-title":"Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer","volume":"37","author":"Cho","year":"2016","journal-title":"Tumor Biol"},{"key":"10.1016\/j.radonc.2023.110030_b0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0080","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2023.110030_b0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.110030_b0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0095","article-title":"Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy","author":"Wang","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109934","article-title":"Hwan Kim, Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy","author":"Yang","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.radonc.2021.12.016","article-title":"Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab","volume":"167","author":"Thor","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0120","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.radonc.2023.110030_b0125","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), 2017."},{"key":"10.1016\/j.radonc.2023.110030_b0130","unstructured":"Harrell Jr FE, rms: Regression Modeling Strategies; 2023. https:\/\/CRAN.R-project.org\/package=rms."},{"key":"10.1016\/j.radonc.2023.110030_b0135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/1097-0142(197603)37:3<1417::AID-CNCR2820370324>3.0.CO;2-N","article-title":"The effect of radiation therapy on lymphocyte subpopulations in cancer patients","volume":"37","author":"Raben","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110030_b0140","first-page":"200","article-title":"Characteristics of the lymphopenia induced by radiotherapy","volume":"23","author":"Campbell","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.radonc.2023.110030_b0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2023.110030_b0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.radonc.2023.110030_b0155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.adro.2017.01.008","article-title":"The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients","volume":"2","author":"McNew","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0160","doi-asserted-by":"crossref","first-page":"S2474","DOI":"10.21037\/jtd.2018.07.29","article-title":"Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy","volume":"10","author":"Yegya-Raman","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.radonc.2023.110030_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2020.04.054","article-title":"Kong, Ultra-high dose rate effect on circulating immune cells: a potential mechanism for FLASH effect?","volume":"149","author":"Jin","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110030_b0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110030_b0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijrobp.2015.09.022","article-title":"Thoracic vertebral body irradiation contributes to acute hematologic toxicity during chemoradiation therapy for non-small cell lung cancer","volume":"94","author":"Deek","year":"2016","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"5","key":"10.1016\/j.radonc.2023.110030_bib183","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cllc.2023.03.013","article-title":"Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System","volume":"24","author":"Yegya-Raman","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110030_bib184","article-title":"Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation","author":"Yegya-Raman","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T09:09:37Z","timestamp":1734253777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"alternative-id":["S0167814023093374"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110030","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110030"}}